Skip to main content
Monday, November 16, 2026Nov 16

This story is exclusive to subscribers.

International drug trial at CHI Memorial could ‘revolutionize’ stroke care, Chattanooga doctor says

Staff photo by Matt Hamilton / Dr. Tom Devlin is pictured at a Chattanooga Rotary Club meeting in 2022. Devlin serves as the principal investigator for the U.S. as part of an international trial for a new drug to treat stroke.
Staff photo by Matt Hamilton / Dr. Tom Devlin is pictured at a Chattanooga Rotary Club meeting in 2022. Devlin serves as the principal investigator for the U.S. as part of an international trial for a new drug to treat stroke.


An international trial for a new drug that combines clot-busting and nerve-protecting effects into one treatment for stroke and extends the treatment window to 24 hours is underway at CHI Memorial.

Dr. Thomas Devlin, medical director of the CHI Memorial Neuroscience Institute, said that if the new drug is proven effective, it would revolutionize therapy for strokes caused by blood clots, which account for 80% of strokes. That’s because the two main existing treatments for that type of stroke — mechanically removing large clots through surgery or using a standard clot-busting drug — are restrictive.

Most small and mid-size hospitals aren’t equipped to perform the surgery that removes the clot — known as a mechanical thrombectomy — and a lot of patients aren’t candidates for that procedure because their clot isn’t big enough or in a place it can be reached, Devlin said. Moreover, less than 50% of patients who receive mechanical thrombectomy regain functional independence, studies show.

(READ MORE: Chattanooga researchers find AI cellphone app expedites stroke care)